Between 1997 and 2002, 48 data sets from the hippocampus were produced on samples from the Stanley Neuropathology Consortium. From these data sets, 224 total measures were available from the various subdivisions of the hippocampus. An integrative analysis of these measures was performed using a multivariate, nonparametric analysis of variance (ANOVA). ANOVA with correction for multiple comparisons indicated that parvalbumin-containing cells in CA2 were reduced in schizophrenia and bipolar disorder. In addition, reelin protein in the molecular layer of the dentate gyrus was decreased in schizophrenia, bipolar disorder, and depression at the trend level of statistical significance (P ¼ 0.065). These results strongly suggest a dysfunction of inhibitory GABA-ergic interneurons in severe mental illness. Without correction for multiple comparisons, 31 measures were abnormal in at least one disease, whereas 11 measures would be expected to appear abnormal by chance. Abnormal molecules included measures of synaptic density or neuronal plasticity (reelin, SNAP-25, BDNF, Complexin I and II), as well as parvalbumin, tyrosine receptor kinase A, glucocorticoid receptors, glutamate NR1 receptor subunits, serotonin 5HT2 A and 5HT1 B receptors, and dopamine D 5 receptors.
The Stanley Brain Collection and Neuropathology Consortium have been described in previous publications. [1] [2] [3] Briefly, the Stanley Neuropathology Consortium contains 15 cases each from individuals with schizophrenia, bipolar disorder, major depressive disorder without psychotic features, and normal controls. These groups are matched for age, sex, race, postmortem interval (PMI), mRNA quality, brain pH, and hemisphere. Since 1996, the 60 matched specimens that constitute the Neuropathology Consortium have been made available to research groups around the world. All investigators receive coded tissue samples and performed their assays in a blinded fashion. Investigators receive the code after submitting their data to the Stanley Medical Research Institute (SMRI) and they are then free to individually interpret and publish their findings. All data are stored in a master database at SMRI in order to summarize and integrate the findings of the individual investigators.
The hippocampus has long been considered an anatomical area involved in the pathophysiology of mental disorders, especially schizophrenia. 4 The literature on hippocampal abnormalities in unipolar depression and bipolar disorder is less extensive, although recent theories of altered hippocampal neuroplasticity and cellular adaptations to stress in these disorders have attractive heuristic value. 5, 6 The purpose of the present paper is to summarize the molecular and cellular measures that have been measured in the hippocampus from the Stanley Consortium.
Methods

Tissue samples
Tissue was dissected by the Stanley Laboratory staff from the anterior one-third of the hippocampus at the level of the uncus, but including the dentate gyrus granule cells, and from the middle one-third of the hippocampus at the level of the lateral geniculate nucleus. Fixed blocks were embedded in paraffin and cut in the coronal plane at 10 mm. Frozen blocks were cryo-sectioned in the coronal plane at 14 mm, thaw-mounted on gelatin-coated slides, and stored at À801C. Anatomically matched sets of slides were assembled by the Stanley Laboratory and sent to the research laboratories. The researchers then took their measurements from the various subfields based on standard anatomical criteria.
Investigators using the Stanley Neuropathology Consortium gave signed consent to have their data merged into a master data set at the SMRI and to have their data published. The terms and conditions for use of SMRI tissue samples and the agreement signed by all investigators can be viewed at www.stanleyresearch.org. Space does not permit a listing of all investigators that contributed to this work, but readers who desire contact with the original investigators can request this information from the authors.
All data collected from anterior and mid-hippocampus were gathered into an integrative database and were examined together. A variety of techniques (for example, radioligand binding, immunoblot, and in situ hybridization) were performed using several possible tissue conditions (frozen or fixed sections or tissue blocks). Measures were only included in this analysis if the assays used to measure them produced quantitative and continuous measures, and if there were data available for an arbitrarily defined majority of cases (n454, which equals 490% complete data). Data summarized in this paper do not contain all experimental results for hippocampal specimens, as work in a number of laboratories is still ongoing. As of June 2002, 48 data sets had been obtained for subdivisions of the hippocampus, including the dentate gyrus, CA1-CA4 and the subiculum. When data from the subdivisions were counted separately, there were 352 total measures, of which 224 had n454; which were used for further analysis. These measures are listed in Table 1 .
Nonparametric analyses of variance
All measures were first subjected to an imputation procedure for missing data. Missing values were estimated using the 'hot-deck' procedure within the Partek, Inc. software package (St Louis, MO, USA, www.partek.com). All measures were then tested for normality of distribution. Measures were tested for skewness, kurtosis and with the omnibus test using the NCSS program (Kaysville, UT, USA). In order to be considered as having a normal distribution, all three of these tests were required to confirm the lack of significant difference from normality. In all, 47% of the measures failed to satisfy criteria for a normal distribution.
Since measures that were not normally distributed could not be combined with normally distributed data in a MANOVA, the entire set of measures was tested with individual nonparametric Kruskal-Wallis H tests. This was performed with the Partek program with and without the application of a Dunn-Sidak correction for multiple comparisons. The H values for each of the measures tested are displayed in Table 1 . This analysis differed from previous summaries of prefrontal 2 and cingulate 3 data, in which parametric analyses were performed and a simple Bonferroni correction for multiple comparisons was employed. Thus, results from this summary may not be directly comparable with results from previous summaries.
Covariance
To examine for effects of continuous confounding measures, we performed Spearman's correlations on measures that emerged as significant with the nonparametric analyses of variance. There were nine continuous confounding measures available for this analysis (postmortem interval (PMI), age, estimated lifetime exposure to neuroleptics, age of illness onset, illness duration, brain pH, brain weight, and freezer or fixation storage time). There were also three noncontinuous confounding measures (hemisphere, gender, and any current or past history of substance abuse) available for analysis. These were used as grouping measures for Student's ttests for any abnormal measure.
Results
Analyses of variance (ANOVA)
Two of the 224 measures were associated with statistically significant (Po0. 05) group differences after correction for multiple comparisons: the total number of immunolabeled parvalbumin neurons in CA2 (H ¼ 19.33, P ¼ 0.015), and the density of immunolabeled parvalbumin-positive neurons in CA2 (H ¼ 19.67, P ¼ 0.02). There was also a group difference in reelin immunolabeled cells in the molecular layer of the dentate gyrus at the trend level of statistical significance (H ¼ 17.31, P ¼ 0.065). All other measures were associated with corrected P-values greater than 0.10.
Post hoc testing with Mann-Whitney U tests revealed significant differences between individual diagnostic groups as displayed in Table 2 . Fold change (D ¼ disease median/control median) is also listed in Table 2 . Fold-change values of less than 1 indicate that the disease median is reduced compared to the control median, and values greater than 1 indicate that the disease median is increased relative to the control median. Without correction for multiple comparisons, 31 measures (13.8% of the total) were significantly abnormal in at least one disease, whereas 11 would be expected to occur by chance. Fold changes for each of these measures relative to normal controls are displayed in Table 3 .
Covariance
There were a number of weak but significant correlations between abnormal measures and various continuous confounding measures. These are displayed in Table 4 . There were no significant differences between male and female subjects or between left and right sides of the brain for any of the measures identified as abnormal in these analyses. Subjects with a history of substance abuse had a significantly lower value of parvalbumin-positive cell density in CA4 (P ¼ 0.04) and of glucocorticoid receptor mRNA in the dentate gyrus (P ¼ 0.01), when compared to subjects who had not abused illicit drugs.
Discussion
We have attempted to summarize a large body of data that has been produced on the hippocampus from Stanley Neuropathology Consortium. In a nonparametric comparison of the four diagnostic groups contained in the Consortium, only two of 224 measures attained statistical significance after correction for multiple comparisons. In a post hoc analysis, both the number and the density of parvalbuminpositive neurons were decreased in the CA2 subfield in samples from subjects with bipolar disorder; the densities of these neurons in CA2 were also reduced in samples from subjects with schizophrenia. A third measure, reelin protein in the molecular layer of the dentate gyrus, was reduced at a trend level of significance in samples from subjects with bipolar disorder, schizophrenia, and major depression. These measures therefore are the most robustly abnormal in this conservative analysis and will be discussed in greater detail. Parvalbumin, and other calcium binding proteins that label specific populations of inhibitory interneurons, have been examined previously in several postmortem collections from psychiatric patients. 7 Data concerning parvalbumin and calretinin from Stanley Consortium hippocampal samples have been reported previously by the primary investigators, 8 who described significant reductions in the density of parvalbumin-containing cells in all hippocampal subfields for schizophrenia, and in the CA1 subfield for subjects with bipolar disorder. Our reanalysis of these data in light of the total body of measurements made in these samples differs somewhat from that of the original authors. Zhang and Reynolds used parametric analyses of variance and post hoc t-tests; we performed nonparametric analyses with these data for the reasons mentioned previously and corrected for multiple comparisons. These procedures restricted the statistical significance of the group differences in cell density to the CA2 subfield in samples from schizophrenic patients. The total number of parvalbumin-positive neurons (uncorrected for tissue volume) was reduced in CA2 of schizophrenia and bipolar disorder. Although the significance of this finding in the absence of a correction for postmortem tissue volume is difficult to interpret, we have reported this result separately because of the significant methodological problems associated with determining cell density using nonstereological methods. The total number of parvalbumin-positive cells in CA2 was negatively correlated with freezer storage time and was positively correlated with brain pH. Parvalbumin cell density in CA2 was negatively correlated with PMI. This suggests that the immunohistochemical staining of parvalbumin decreases as samples are stored for longer periods of time, become more acidic after death, and are obtained at longer PMIs. Since the mean values for pH and PMI for the four groups comprising the Stanley Consortium do not differ significantly, 1 it is unlikely that these confounding measures contribute a major portion of the variance between diagnostic groups. The Stanley Consortium cases were not, however, matched for freezer nor fixation storage time. A comparison of the bipolar, depressed, and schizophrenic diagnostic groups revealed a trend level of significance for storage time (F ¼ 3.11, P ¼ 0.055). The mean storage time for cases of depression (434.0 days) was substantially less than that for bipolar disorder (620.5 days) and schizophrenia (621.1 days). Thus, the lack of significant reductions in parvalbumin cell density in the depressed subjects may be partly explained by the lower freezer storage time in this group.
Other studies of parvalbumin in the hippocampus from subjects with severe mental disorders are not available, but Benes et al 9 reported a reduction in the number and density of nonpyramidal neurons in the CA2 subfield from subjects with schizophrenia and bipolar disorder. These authors have also reported a number of other intriguing findings in the CA2 subfield. These include: an increase in the density of GABA A receptors; 9 a positive correlation between neuroleptic exposure and glutamate decarboxylase 65 immunoreactivity; 10 a reduction in tyrosine hydroxylase immunoreactivity that is also negatively correlated with antipsychotic exposure; 11 and a reduction in the density of GluR 5,6 and 7 subunits 12 Taken together, these results suggest that a cellular deficit of inhibitory interneurons occurs in severe mental illnesses, although a molecular abnormality of parvalbumin itself is not conclusively ruled out. Abnormal glutamatergic and dopaminergic interactions with these interneurons may be particularly notable in CA2, and neuroleptic therapy may compensate for some of these abnormalities. The convergence of data from these findings in the CA2 subfield is interesting, since CA2/CA3 neurons are an important information processing point between the dentate gyrus and the subiculum. 13 However the CA2 subfield does not appear to have a developmental trajectory separate from that of other hippocampal subfields, 14 and does not appear to have an unusual degree of vulnerability to degenerative processes or hypoxia. 15 Indeed, other commentators have made the case that molecular findings in the CA4-CA3 subfields, 4 and in the subiculum 16 may have more direct relevance for mental disorders.
Reduced density of parvalbumin containing interneurons has also been reported in prefrontal cortical samples, 17 but not in anterior cingulate samples 18 from the Stanley Consortium. Thus, abnormal inhibitory interneuron activity may not be specific to the hippocampus in severe mental illness. A more detailed body of cytoarchitectural research will be necessary to elucidate this hypothesis in neocortical regions. The parvalbumin gene has been mapped to human chromosome 22q12-q13.1. 19 Segments of chromosome 22q11 have been linked to the schizophrenic phenotype, but these would not appear to cosegregate with the parvalbumin gene. 20 Association studies of the parvalbumin gene to schizophrenia and mood disorders have not been reported.
Reelin is an extracellular matrix protein that is involved in cell positioning and migration during brain development. In reeler mice with impaired motor coordination and tremor, distorted cerebellar and neocortical lamination is associated with a deletion of the reelin (Reln) gene and decreased expression of reelin protein. 21 A separate analysis of the reelin data examined here has been published by the original investigators. 22 In their analysis of quantitative immunocytochemical data, reelin-positive cell densities were reduced in the dentate molecular layer and in CA4 in schizophrenia, and in CA4 in bipolar disorder. The investigators' results with parametric analyses of variance were consistent with the nonparametric techniques employed here, except that only the dentate molecular layer data approached statistical significance after correction for multiple comparisons, and reductions in this area were observed in all three major psychiatric illnesses. Reelin protein levels were negatively correlated with PMI and illness duration, and were positively correlated with the age of illness onset. This suggests that reelin protein levels decline when samples are collected after long PMIs. It also suggests that a putative reelin deficit in severe mental illness may be progressive. That is, reelin levels decline as illness duration becomes longer, and reelin levels are higher in subjects who had a later age of disease onset. As mentioned above, mean values for PMI in Stanley Consortium samples were matched between the diagnostic groups. There was also no significant difference between diagnostic groups for illness duration. However, the mean age of illness onset for subjects with depression (33.9 years) was significantly higher than that for bipolar (21.5 years) disorder or the schizophrenic (23.2 years). Thus, the failure of Fatemi et al 22 to find significant differences in the depressed subjects could be partially explained by the difference in the age of illness onset.
A significant decrease of reelin RNA and reelinpositive cells has been reported in prefrontal cortical and cerebellar samples from subjects with schizophrenia and bipolar disorder in the Stanley Consortium. 23 Impagnatiello et al, 24 using a different brain collection, found that reelin RNA levels were reduced in prefrontal, temporal, cerebellar, hippocampal, and striatal samples from subjects with schizophrenia. Reelin protein levels were also reduced in the temporal samples and in superficial frontal cortical layers in schizophrenia in this study, but data regarding subdivisions of the hippocampus was not reported. Eastwood et al 25 have reported a trend towards reduced reelin RNA in the cerebellum of subjects with schizophrenia, and that reelin RNA was inversely correlated with semaphorin 3A RNA. Preliminary data also suggest that plasma reelin protein and its isoforms may be reduced in schizophrenia. 26 Taken together, these results constitute evidence from independent investigators and independent postmortem collections, implicating decreased reelin gene and protein expression in psychotic disorders.
The reelin gene is located on chromosome 7q22, which has not been associated with schizophrenia or bipolar disorder in prior linkage analyses. An association of a single-nucleotide polymorphism at the 5' promoter region of the reelin gene with the schizophrenia phenotype has been reported, 27 but was not confirmed in a larger case-control association study. 28 The fact that reelin was most abnormal in the dentate gyrus granule cells is notable in light of other findings. Secretion of reelin by Cajal-Retzius interneurons in the marginal zone of the developing cortex is thought to act as a stop signal for migrating neurons. Reduced reelin RNA levels in the dentate gyrus from patients with temporal lobe epilepsy may be related to the degree of granule cell dispersion in this disorder 29, 30 and reeler mice have significant disruptions in the architecture of dentate granule cells. 31 Although gross disarray of dentate granule cell architecture has not been reported in severe mental illness, a subtler defect than that seen in epilepsy may be present in schizophrenia, bipolar disorder, and major depression. The dentate granule cells are potentially relevant to all three disease phenotypes as they receive input from the entorhinal cortex and then project to the CA subdivisions of the hippocampus via the mossy fibers.
As noted above, Table 3 contains a list of abnormal measures before correction for multiple comparisons was made. Several of these measures have been discussed at length by individual investigators and will not be discussed further here. These include parvalbumin, 8 the complexins, 32 glucocorticoid receptors, 33 NMDA-NR1 receptors, 34 and SNAP-25.
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Tyrosine receptor kinase A (trkA) was decreased in CA2 and CA4 in schizophrenia and bipolar disorder. TrkA and its ligand, nerve growth factor (NGF), have been suggested to be involved in severe mental illness based on preliminary observations in animals and in plasma studies in humans; 36, 37 however, genetic and postmortem studies supporting a role for trkA or NGF are lacking.
Brain-derived neurotrophic factor (BDNF) was also decreased in schizophrenia and bipolar disorder in this analysis. These BDNF results have not been previously published; however, another study using the Stanley Consortium tissue reported a positive association between hippocampal BDNF and antidepressant therapy. 38 Data from the Chen et al study 38 were not included in this meta-analysis because their data-set did not meet entry criteria for completeness. BDNF levels have not been measured in other brain areas from the Stanley Consortium, but Bayer et al 39 have also described an association between antidepressant exposure and trkB RNA (the receptor for BDNF) in the cerebellum. Other studies have supported a role for BDNF and trkB in processes that may be related to severe mental illness such as cognitive function, 40 antipsychotic treatment, 41 and brain morphology. 42 Dopamine D5 receptor RNAs were increased in subjects with bipolar disorder (dentate gyrus, CA1, and subiculum) and with unipolar depression (dentate gyrus and subiculum). Of all the abnormal molecules in this analysis, D5 receptor RNA is the only one that was elevated relative to controls. Prior measurements of dopamine D5 receptor RNA in the hippocampus of psychiatrically ill subjects have not been published. D5 receptor RNA is not altered in prefrontal specimens from the Stanley Consortium. 2 Antipsychotic treatment does not appear to alter D5 receptor RNA in rodents 43 but effects of other psychotropic medications are not known. The D5 receptor gene has been linked to schizophrenia in some studies 44, 45 but a negative study also exists. 46 There has been no reported link of the D5 receptor gene to affective disorders.
Serotonin 5HT 2A receptor RNA was reduced in schizophrenia and bipolar disorder. Prior studies of 5HT 2A receptor RNA in the hippocampus of schizophrenics and bipolar disorder have not been published. Altered levels of hippocampal 5HT 2A receptors have been observed in suicide victims however. 47, 48 Changes in prefrontal 5HT 2A receptors were not observed in the Stanley Consortium, 2,49 but have been observed in other cohorts. 50, 51 Serotonin 5HT 1B receptor RNA measures in CA1 and CA4 were associated with significant Kruskal-Wallis H values in the uncorrected analysis. Post hoc testing revealed that there were no significant differences between disease groups and normal controls. The significant H value for CA1 was explained by a difference between subjects with bipolar disorder and depression, and between subjects with schizophrenia and depression. Likewise, the significant value for 5HT 1B RNA in CA4 was explained by a difference between subjects with schizophrenia and depression. Fold changes and correlations with confounding measures for 5HT 1B in CA1 and CA4 are, therefore, not displayed in Tables 3 and 4 .
In conclusion, we have summarized data currently available on the hippocampus from the Stanley Neuropathology Consortium. Parvalbumin and reelin proteins, both of which are associated with GABAergic inhibitory interneurons, were the most robust abnormal findings. Without correction for multiple comparisons, a total of 32 measures were abnormal in at least one disease. These abnormal measures were related to inhibitory interneurons, synapse formation, neuronal growth and plasticity, and glucocorticoid and other neurotransmitter receptors.
As was also observed in a summary of data from the prefrontal cortex, 2 schizophrenia was associated with the greatest number of abnormal measures (23) . There was considerable overlap between the number of abnormal measures observed in schizophrenia and the number observed in bipolar disorder (22) . Subjects with depression exhibited relatively few abnormal changes (6) . The phenotypic similarities between individuals with bipolar disorder and schizophrenia in the Stanley Consortium have been commented upon previously, 2, 3 and may explain the significant overlap in molecular neuropathology for these two disorders. The abnormal hippocampal measures in this summary are also similar to those described in prefrontal and cingulate cortices in terms of their directionality, with the majority of abnormalities being reduced compared to controls. This consistent directionality suggests a widespread reduction of gene expression in schizophrenia and bipolar disorder and argues against these findings being false positives due to purely stochastic effects. The probability that 30 of 31 measurements would be reduced relative to normal controls is remotely small (ie, approximately 1 2 30 . It is also important to note that freezer and fixation storage time, postmortem interval, and brain pH were important confounding measures for many of the abnormal measures. It is hoped that future research on the molecular abnormalities in this summary will delineate which of them will become targets for new treatments or candidate genes.
